Key facts
- It has raised $12.7M; the latest was Seed Round ($2.0M) in Apr 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for RLL Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for RLL Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RLL Bio
Operator of a biotechnology company intended to extend survival and improve the quality of life for cancer patients through the development of next-generation, low-toxicity therapeutics. The company offers a first-in-class oral drug, with a mechanism of action that selectively targets cancer cell proliferation while sparing healthy cells, enabling customers to benefit from more effective treatment outcomes, reduced toxic side effects and minimized risk of drug resistance.
- Sector
- Healthcare
- HQ
- Lutherville Timonium, MD, United States
- Website
- rllbio.com/
- Ownership
- Privately Held (backing)
RLL Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RLL Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RLL Bio in its N-PORT filings yet. We sweep new filings monthly.